Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2023 Filed Feb 25, 2023 01:18 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 137,760 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002811 · doc4.xml · derivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,760 Underlying: Common Stock · 137,760 shares Expires 2028-02-23 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:22 UTC |
Fonseca LidiaExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 37,966 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002812 · doc4.xml · derivative · entry 3 Fonseca Lidia · CIK 0001454944 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,966 Underlying: Common Stock · 37,966 shares Expires 2030-02-23 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:22 UTC |
Fonseca LidiaExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 43,624 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002812 · doc4.xml · derivative · entry 2 Fonseca Lidia · CIK 0001454944 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,624 Underlying: Common Stock · 43,624 shares Expires 2028-02-23 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:27 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 21,581 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002813 · doc4.xml · derivative · entry 7 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,581 Underlying: Common Stock · 21,581 shares Expires 2030-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:27 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 24,797 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002813 · doc4.xml · derivative · entry 6 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,797 Underlying: Common Stock · 24,797 shares Expires 2028-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:35 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 69,938 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002814 · doc4.xml · derivative · entry 4 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,938 Underlying: Common Stock · 69,938 shares Expires 2030-02-23 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:35 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 80,360 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002814 · doc4.xml · derivative · entry 3 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,360 Underlying: Common Stock · 80,360 shares Expires 2028-02-23 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:45 UTC |
MALIK AAMIRExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 89,920 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002815 · doc4.xml · derivative · entry 3 MALIK AAMIR · CIK 0001881510 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,920 Underlying: Common Stock · 89,920 shares Expires 2030-02-23 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:45 UTC |
MALIK AAMIRExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 103,320 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002815 · doc4.xml · derivative · entry 2 MALIK AAMIR · CIK 0001881510 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,320 Underlying: Common Stock · 103,320 shares Expires 2028-02-23 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:52 UTC |
McDermott MichaelExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 39,965 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002816 · doc4.xml · derivative · entry 6 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,965 Underlying: Common Stock · 39,965 shares Expires 2030-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:52 UTC |
McDermott MichaelExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 45,920 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002816 · doc4.xml · derivative · entry 5 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,920 Underlying: Common Stock · 45,920 shares Expires 2028-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:58 UTC |
Pao WilliamExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 69,938 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002817 · doc4.xml · derivative · entry 3 Pao William · CIK 0001919343 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,938 Underlying: Common Stock · 69,938 shares Expires 2030-02-23 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:58 UTC |
Pao WilliamExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 80,360 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002817 · doc4.xml · derivative · entry 2 Pao William · CIK 0001919343 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,360 Underlying: Common Stock · 80,360 shares Expires 2028-02-23 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 02:03 UTC |
SAHNI PAYALExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 39,965 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002818 · doc4.xml · derivative · entry 7 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,965 Underlying: Common Stock · 39,965 shares Expires 2030-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 02:03 UTC |
SAHNI PAYALExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 45,920 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002818 · doc4.xml · derivative · entry 6 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,920 Underlying: Common Stock · 45,920 shares Expires 2028-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 02:17 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 37,966 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002831 · doc4.xml · derivative · entry 7 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,966 Underlying: Common Stock · 37,966 shares Expires 2030-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 02:17 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 43,624 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002831 · doc4.xml · derivative · entry 6 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,624 Underlying: Common Stock · 43,624 shares Expires 2028-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 02:34 UTC |
Hwang AngelaPresident, Global Biopharmaceu
|
GrantStock Appreciation Rights · Derivative | 89,920 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002832 · doc4.xml · derivative · entry 8 Hwang Angela · CIK 0001725474 · President, Global Biopharmaceu 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,920 Underlying: Common Stock · 89,920 shares Expires 2030-02-23 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 02:34 UTC |
Hwang AngelaPresident, Global Biopharmaceu
|
GrantStock Appreciation Rights · Derivative | 103,320 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002832 · doc4.xml · derivative · entry 7 Hwang Angela · CIK 0001725474 · President, Global Biopharmaceu 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,320 Underlying: Common Stock · 103,320 shares Expires 2028-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:11 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 61,994 | $42.38 | $2,627,305.72 |
DisclosureSEC source: 0001225208-23-002808 · doc4.xml · nonDerivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,477 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:14 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Exercise / conversionStock Appreciation Rights · Derivative | 10,456 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001225208-23-002809 · doc4.xml · derivative · entry 5 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,456 shares Expires 2023-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:14 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Tax withholdingCommon Stock | 6,365 | $43.70 | $278,150.50 |
DisclosureSEC source: 0001225208-23-002809 · doc4.xml · nonDerivative · entry 3 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,640 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:14 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Tax withholdingCommon Stock | 1,579 | $42.38 | $66,918.02 |
DisclosureSEC source: 0001225208-23-002809 · doc4.xml · nonDerivative · entry 2 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,005 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:14 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Exercise / conversionCommon Stock | 10,456 | $30.17 | $315,457.52 |
DisclosureSEC source: 0001225208-23-002809 · doc4.xml · nonDerivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:18 UTC |
Dolsten MikaelPresident R&D
|
Tax withholdingCommon Stock | 32,592 | $42.38 | $1,381,248.96 |
DisclosureSEC source: 0001225208-23-002811 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,223 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:27 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 31,558 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001225208-23-002813 · doc4.xml · derivative · entry 5 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,558 shares Expires 2023-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:27 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 19,211 | $43.70 | $839,520.70 |
DisclosureSEC source: 0001225208-23-002813 · doc4.xml · nonDerivative · entry 3 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,819 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:27 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 4,526 | $42.38 | $191,811.88 |
DisclosureSEC source: 0001225208-23-002813 · doc4.xml · nonDerivative · entry 2 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,030 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:27 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionCommon Stock | 31,558 | $30.17 | $952,104.86 |
DisclosureSEC source: 0001225208-23-002813 · doc4.xml · nonDerivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:35 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 19,878 | $42.38 | $842,429.64 |
DisclosureSEC source: 0001225208-23-002814 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,535 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:52 UTC |
McDermott MichaelExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 13,307 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001225208-23-002816 · doc4.xml · derivative · entry 4 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,307 shares Expires 2023-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:52 UTC |
McDermott MichaelExecutive Vice President
|
Tax withholdingCommon Stock | 8,101 | $43.70 | $354,013.70 |
DisclosureSEC source: 0001225208-23-002816 · doc4.xml · nonDerivative · entry 3 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,921 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:52 UTC |
McDermott MichaelExecutive Vice President
|
Tax withholdingCommon Stock | 1,935 | $42.38 | $82,005.30 |
DisclosureSEC source: 0001225208-23-002816 · doc4.xml · nonDerivative · entry 2 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,022 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:52 UTC |
McDermott MichaelExecutive Vice President
|
Exercise / conversionCommon Stock | 13,307 | $30.17 | $401,472.19 |
DisclosureSEC source: 0001225208-23-002816 · doc4.xml · nonDerivative · entry 1 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:03 UTC |
SAHNI PAYALExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 15,209 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001225208-23-002818 · doc4.xml · derivative · entry 5 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,209 shares Expires 2023-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:03 UTC |
SAHNI PAYALExecutive Vice President
|
Tax withholdingCommon Stock | 9,259 | $43.70 | $404,618.30 |
DisclosureSEC source: 0001225208-23-002818 · doc4.xml · nonDerivative · entry 3 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,206 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:03 UTC |
SAHNI PAYALExecutive Vice President
|
Tax withholdingCommon Stock | 2,206 | $42.38 | $93,490.28 |
DisclosureSEC source: 0001225208-23-002818 · doc4.xml · nonDerivative · entry 2 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,465 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:03 UTC |
SAHNI PAYALExecutive Vice President
|
Exercise / conversionCommon Stock | 15,209 | $30.17 | $458,855.53 |
DisclosureSEC source: 0001225208-23-002818 · doc4.xml · nonDerivative · entry 1 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:17 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 76,043 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001225208-23-002831 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,043 shares Expires 2023-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:17 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 46,291 | $43.70 | $2,022,916.70 |
DisclosureSEC source: 0001225208-23-002831 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,195 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:17 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 13,007 | $42.38 | $551,236.66 |
DisclosureSEC source: 0001225208-23-002831 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,486 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:17 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionCommon Stock | 76,043 | $30.17 | $2,294,217.31 |
DisclosureSEC source: 0001225208-23-002831 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:34 UTC |
Hwang AngelaPresident, Global Biopharmaceu
|
Exercise / conversionStock Appreciation Rights · Derivative | 57,032 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001225208-23-002832 · doc4.xml · derivative · entry 6 Hwang Angela · CIK 0001725474 · President, Global Biopharmaceu 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,032 shares Expires 2023-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:34 UTC |
Hwang AngelaPresident, Global Biopharmaceu
|
Tax withholdingCommon Stock | 34,718 | $43.70 | $1,517,176.60 |
DisclosureSEC source: 0001225208-23-002832 · doc4.xml · nonDerivative · entry 3 Hwang Angela · CIK 0001725474 · President, Global Biopharmaceu 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,268 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:34 UTC |
Hwang AngelaPresident, Global Biopharmaceu
|
Tax withholdingCommon Stock | 8,041 | $42.38 | $340,777.58 |
DisclosureSEC source: 0001225208-23-002832 · doc4.xml · nonDerivative · entry 2 Hwang Angela · CIK 0001725474 · President, Global Biopharmaceu 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,986 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:34 UTC |
Hwang AngelaPresident, Global Biopharmaceu
|
Exercise / conversionCommon Stock | 57,032 | $30.17 | $1,720,655.44 |
DisclosureSEC source: 0001225208-23-002832 · doc4.xml · nonDerivative · entry 1 Hwang Angela · CIK 0001725474 · President, Global Biopharmaceu 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:14 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 228 | $42.95 | $9,792.60 |
DisclosureSEC source: 0001225208-23-002421 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,727 Underlying: Common Stock · 228 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:19 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 2,037 | $42.95 | $87,489.15 |
DisclosureSEC source: 0001225208-23-002424 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,558 Underlying: Common Stock · 2,037 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:32 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 1,488 | $42.95 | $63,909.60 |
DisclosureSEC source: 0001225208-23-002431 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,707 Underlying: Common Stock · 1,488 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 23:39 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 41 | $47.71 | $1,956.11 |
DisclosureSEC source: 0001225208-23-000627 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,522 Underlying: Common Stock · 41 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.